Pharmacogenetic Study in Gastric Cancer Patients Treated with Adjuvant Fluorouracil/Leucovorin or Epirubicin/Cisplatin/Fluorouracil Before and After Chemoradiation on CALGB 80101 (Alliance)
      QxMD      Google Scholar   
Citation:
Pharmacogenet Genomics vol 31 (9) 215-220
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
11
Parents:
2269  
Children:
None
Program:
TRP
Primary Committee:
PPP
Sec. Committees:
GI    
Pharmas:
 
Grants:
U10 CA180821, U10 CA180882, U24 CA196171, U01GM61390, U01GM61393, U01GM63440; U10CA031983, U10CA060138, UG1CA233160, UG1CA233180, UG1CA233253, UG1CA233327, UG1CA233337, UG1CA233373, U10CA180857; U10CA180863 (CCTG); U10CA180868 (NRG Oncology/RTOG); U10CA180820 (ECOG-ACRIN); and U10CA180888 (SWOG)  
Corr. Author:
 
Authors:
                                 
Networks:
FL003, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC010, NC002   
Study
CALGB-80101
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
pharmacogenetic, gastric, cancer, polymorphism, gene, toxicity